Dembicka-Mączka Diana, Gryka-Deszczyńska Magdalena, Sitkiewicz Jacek, Makara Aleksander, Fiegler-Rudol Jakub, Wiench Rafał
Dental Office-Artistic Smile Studio, 61/1 Krakowska Street, 33-100 Tarnów, Poland.
Dentalove Clinic Ltd., 19 Borzymowska Street, 03-565 Warsaw, Poland.
J Clin Med. 2025 Jun 19;14(12):4371. doi: 10.3390/jcm14124371.
: Snoring and mild to moderate obstructive sleep apnoea (OSA) are common sleep-related breathing disorders with increasing demand for minimally invasive treatment options. This study aimed to systematically evaluate the efficacy and safety of erbium:yttrium-aluminium-garnet (Er:YAG) laser therapy for these conditions. : A systematic review and meta-analysis were conducted in line with PRISMA guidelines. Studies published between 2015 and 2025 were retrieved from major biomedical databases based on predefined inclusion criteria. Data were extracted on treatment outcomes, laser parameters, patient characteristics, and adverse effects. : Fifty-six studies were included. Er:YAG laser treatment, particularly in non-ablative SMOOTH and long-pulse modes, significantly reduced snoring intensity and improved subjective sleep quality. High patient satisfaction (65-85%) and a favourable safety profile were observed, with adverse effects generally mild and transient. Therapeutic effects typically lasted 12-24 months, though 25-40% of patients required maintenance sessions. Treatment success was associated with BMI, oropharyngeal anatomy, smoking status, and baseline apnoea-hypopnoea index scores (AHI 5-30 events/hour). : Er:YAG laser therapy appears to be a safe and effective short- to medium-term treatment for selected patients with snoring or mild to moderate OSA. Optimising patient selection and treatment protocols may enhance long-term outcomes. Based on moderate-quality evidence for the immediate effects and safety profile, but low to very low quality evidence for long-term outcomes, erbium:yttrium-aluminium-garnet laser treatment appears to be a potentially effective and well-tolerated option for achieving short- to medium-term improvement in carefully selected patients with primary snoring or mild to moderate obstructive sleep apnoea. The practical significance of these findings lies in the refinement of candidate selection criteria, laser parameter settings, and the development of optimal protocols for long-term snoring control.
打鼾以及轻至中度阻塞性睡眠呼吸暂停(OSA)是常见的与睡眠相关的呼吸障碍,对微创治疗方案的需求日益增加。本研究旨在系统评估铒:钇铝石榴石(Er:YAG)激光疗法对这些病症的疗效和安全性。
按照PRISMA指南进行了系统评价和荟萃分析。根据预先确定的纳入标准,从主要生物医学数据库中检索了2015年至2025年发表的研究。提取了有关治疗结果、激光参数、患者特征和不良反应的数据。
纳入了56项研究。Er:YAG激光治疗,尤其是非消融性SMOOTH模式和长脉冲模式,显著降低了打鼾强度并改善了主观睡眠质量。观察到患者满意度较高(65 - 85%)且安全性良好,不良反应通常轻微且短暂。治疗效果通常持续12 - 24个月,不过25 - 40%的患者需要维持治疗。治疗成功与体重指数、口咽解剖结构、吸烟状况以及基线呼吸暂停低通气指数评分(AHI为5 - 30次/小时)有关。
Er:YAG激光疗法似乎是针对特定打鼾或轻至中度OSA患者的一种安全有效的短期至中期治疗方法。优化患者选择和治疗方案可能会提高长期疗效。基于对即刻疗效和安全性的中等质量证据,但对长期疗效的证据质量低至极低,铒:钇铝石榴石激光治疗似乎是一种潜在有效的且耐受性良好的选择,可使精心挑选的原发性打鼾或轻至中度阻塞性睡眠呼吸暂停患者在短期至中期得到改善。这些发现的实际意义在于完善候选者选择标准、激光参数设置以及制定长期控制打鼾的最佳方案。